MFS
ENGN icon

Mirabella Financial Services’s enGene Therapeutics ENGN Stock Holding History

Mirabella Financial Services’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$95.1K Buy
+13,962
New +$124K 0.01% 859

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Mirabella Financial Services's ENGN Position: Q1 2026 in Review

Mirabella Financial Services opened a new position in enGene Therapeutics (ENGN) in Q1 2026: 13,962 shares worth $95.1K. The stake represents 0.01% of the portfolio and ranks #859 among its holdings.

61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Mirabella Financial Services held 13,962 shares of enGene Therapeutics worth $95.1K as of Q1 2026.
  • enGene Therapeutics was a new Mirabella Financial Services position in Q1 2026.
  • enGene Therapeutics made up 0.01% of Mirabella Financial Services's portfolio in Q1 2026, its #859 holding.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Mirabella Financial Services's 13F filing for Q1 2026, filed 12 May 2026.